Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.82 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | NCF1 | P14598 | 2/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5230432 | 0.99 | HTR2C (0.80) | HTR2CHTR6GAAMAPK1MTNR1A | |
| SCHEMBL5230934 | 0.95 | HTR2C (0.80) | HTR2CHTR6GAAMAPK1MTNR1A | |
| Hydrochloric Acid SCHEMBL5233992 | 0.94 | HTR2C (0.79) | HTR2CHTR6GAAMAPK1MTNR1A | |
| SCHEMBL5234060 | 0.91 | HTR2C (0.74) | HTR2CHTR6GAAMAPK1MTNR1A | |
| SCHEMBL905809 | 0.90 | HTR2C (1.00) | HTR2CHTR6GAAMAPK1MTNR1A | |
| SCHEMBL905848 | 0.89 | HTR2C (0.78) | HTR2CHTR6GAAMAPK1MTNR1A | |
| Hydrochloric Acid SCHEMBL5233162 | 0.88 | HTR2C (0.77) | HTR2CHTR6GAAMAPK1MTNR1A | |
| SCHEMBL905772 | 0.87 | HTR2C (0.78) | HTR2CHTR6GAAMAPK1MTNR1A | |
| SCHEMBL905774 | 0.87 | HTR2C (0.78) | HTR2CHTR6GAAMAPK1MTNR1A | |
| SCHEMBL5234288 | 0.87 | HTR2C (0.71) | HTR2CHTR6MTNR1AMTNR1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1347979-B1 | INDOLE DERIVATIVES AND THEIR USE AS 5-HT2B AND 5-HT2C RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2007-08-08 | — | — | EP | claimed |
| EP-1347979-A1 | INDOLE DERIVATIVES AND THEIR USE AS 5-HT2B AND 5-HT2C RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-01 | — | — | EP | claimed |
| US-6610685-B2 | (S)-2-(6-ethoxy-2,3-dihydro-1H-3a-aza-cyclopenta(a)inden-8-yl)-1-methyl-ethylamine for example; treating diabetes; in combination with a lipase inhibitor such as orlistat | HOFFMANN-LA ROCHE INC. | 2003-08-26 | — | — | US | claimed |
| US-20020160997-A1 | (S)-2-(6-ethoxy-2,3-dihydro-1H-3a-aza-cyclopenta(a)inden-8-yl)-1-methyl-ethylamine for example; treating diabetes; in combination with a lipase inhibitor such as orlistat | F.HOFFANN-LA ROCHE AG (CH) | 2002-10-31 | — | — | US | claimed |
| WO-2002051844-A1 | INDOLE DERIVATIVES AND THEIR USE AS 5-HT2B AND 5-HT2C RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-04 | — | — | WO | claimed |
| EP-1347979-B1 | INDOLE DERIVATIVES AND THEIR USE AS 5-HT2B AND 5-HT2C RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2007-08-08 | — | — | EP | disclosed |
| EP-1347979-A1 | INDOLE DERIVATIVES AND THEIR USE AS 5-HT2B AND 5-HT2C RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-01 | — | — | EP | disclosed |
| US-6610685-B2 | (S)-2-(6-ethoxy-2,3-dihydro-1H-3a-aza-cyclopenta(a)inden-8-yl)-1-methyl-ethylamine for example; treating diabetes; in combination with a lipase inhibitor such as orlistat | HOFFMANN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020160997-A1 | (S)-2-(6-ethoxy-2,3-dihydro-1H-3a-aza-cyclopenta(a)inden-8-yl)-1-methyl-ethylamine for example; treating diabetes; in combination with a lipase inhibitor such as orlistat | F.HOFFANN-LA ROCHE AG (CH) | 2002-10-31 | — | — | US | disclosed |
| WO-2002051844-A1 | INDOLE DERIVATIVES AND THEIR USE AS 5-HT2B AND 5-HT2C RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160997-A1 | (S)-2-(6-ethoxy-2,3-dihydro-1H-3a-aza-cyclopenta(a)inden-8-yl)-1-methyl-ethylamine for example; treating diabetes; in combination with a lipase inhibitor such as orlistat | PNLIP, LIPA, LPL | HTR2C 502/4885HTR6 421/4885GAA 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.